All TreatGx users now have access to the updated treatment algorithm for Atrial Fibrillation – Rate Control.
The updated Rate Control algorithm provides personalized medication treatment options for each patient based on whether they have certain cardiovascular comorbidities , including those with heart failure with reduced ejection fraction, heart failure with preserved ejection fraction, or hypertension. This algorithm continues to provide personalized dosing and information based on pharmacogenetics, kidney function, and liver function, and now includes an additional beta-blocker, nebivolol.
This update includes information from local and international treatment guidelines for atrial fibrillation, including the American Heart Association, American College of Cardiology Foundation and Heart Rhythm Society 2014 guideline[1], the Canadian Cardiovascular Society and Canadian Heart Rhythm Society 2020 guideline[2], and the European Society of Cardiology 2020 guideline[3].
References
- January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC, Conti JB, Ellinor PT, Ezekowitz MD, Field MEet al:2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation. Circulation 2014, 130(23):e199-e267.
- Andrade JG, Aguilar M, Atzema C, Bell A, Cairns JA, Cheung CC, Cox JL, Dorian P, Gladstone DJ, Healey JSet al:The 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society Comprehensive Guidelines for the Management of Atrial Fibrillation. Canadian Journal of Cardiology 2020.
- Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, Boriani G, Castella M, Dan GA, Dilaveris PEet al:2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). Eur Heart J 2020.